Conglomerates
Compare Stocks
2 / 10Stock Comparison
CRESY vs BIOX
Revenue, margins, valuation, and 5-year total return — side by side.
Agricultural Inputs
CRESY vs BIOX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Conglomerates | Agricultural Inputs |
| Market Cap | $747M | $31M |
| Revenue (TTM) | $1.05T | $318M |
| Net Income (TTM) | $234.51B | $-53M |
| Gross Margin | 42.0% | 39.1% |
| Operating Margin | 62.1% | 0.2% |
| Forward P/E | 9999.0x | — |
| Total Debt | $1.46T | $277M |
| Cash & Equiv. | $250.85B | $33M |
CRESY vs BIOX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Cresud Sociedad Anó… (CRESY) | 100 | 374.7 | +274.7% |
| Bioceres Crop Solut… (BIOX) | 100 | 7.2 | -92.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CRESY vs BIOX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
CRESY carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 0 yrs, beta 1.19, yield 8.2%
- Rev growth 28.5%, EPS growth -99.9%, 3Y rev CAGR 6.0%
- 68.4% 10Y total return vs BIOX's -95.0%
BIOX is the clearest fit if your priority is value.
- Better valuation composite
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 28.5% revenue growth vs BIOX's -28.3% | |
| Value | Better valuation composite | |
| Quality / Margins | 22.3% margin vs BIOX's -16.6% | |
| Stability / Safety | Beta 1.19 vs BIOX's 1.94, lower leverage | |
| Dividends | 8.2% yield; the other pay no meaningful dividend | |
| Momentum (1Y) | +13.6% vs BIOX's -88.4% | |
| Efficiency (ROA) | 4.3% ROA vs BIOX's -6.7%, ROIC 5.7% vs -0.5% |
CRESY vs BIOX — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
CRESY leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
CRESY is the larger business by revenue, generating $1.05T annually — 3307.4x BIOX's $318M. CRESY is the more profitable business, keeping 22.3% of every revenue dollar as net income compared to BIOX's -16.6%. On growth, CRESY holds the edge at +50.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $1.05T | $318M |
| EBITDAEarnings before interest/tax | $670.2B | $21M |
| Net IncomeAfter-tax profit | $234.5B | -$53M |
| Free Cash FlowCash after capex | $116.8B | $37M |
| Gross MarginGross profit ÷ Revenue | +42.0% | +39.1% |
| Operating MarginEBIT ÷ Revenue | +62.1% | +0.2% |
| Net MarginNet income ÷ Revenue | +22.3% | -16.6% |
| FCF MarginFCF ÷ Revenue | +11.1% | +11.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | +50.4% | -16.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +2.6% | -37.3% |
Valuation Metrics
BIOX leads this category, winning 4 of 5 comparable metrics.
Valuation Metrics
On an enterprise value basis, CRESY's 9.7x EV/EBITDA is more attractive than BIOX's 20.0x.
| Metric | ||
|---|---|---|
| Market CapShares × price | $747M | $31M |
| Enterprise ValueMkt cap + debt − cash | $1.6B | $275M |
| Trailing P/EPrice ÷ TTM EPS | 9999.00x | -0.59x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 9.73x | 20.05x |
| Price / SalesMarket cap ÷ Revenue | 1.14x | 0.09x |
| Price / BookPrice ÷ Book value/share | 0.48x | 0.10x |
| Price / FCFMarket cap ÷ FCF | 9.85x | 0.87x |
Profitability & Efficiency
CRESY leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
CRESY delivers a 10.1% return on equity — every $100 of shareholder capital generates $10 in annual profit, vs $-17 for BIOX. CRESY carries lower financial leverage with a 0.66x debt-to-equity ratio, signaling a more conservative balance sheet compared to BIOX's 0.94x. On the Piotroski fundamental quality scale (0–9), CRESY scores 5/9 vs BIOX's 3/9, reflecting solid financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | +10.1% | -16.7% |
| ROA (TTM)Return on assets | +4.3% | -6.7% |
| ROICReturn on invested capital | +5.7% | -0.5% |
| ROCEReturn on capital employed | +6.4% | -0.8% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 3 |
| Debt / EquityFinancial leverage | 0.66x | 0.94x |
| Net DebtTotal debt minus cash | $1.21T | $244M |
| Cash & Equiv.Liquid assets | $250.9B | $33M |
| Total DebtShort + long-term debt | $1.46T | $277M |
| Interest CoverageEBIT ÷ Interest expense | 3.48x | -0.07x |
Total Returns (Dividends Reinvested)
CRESY leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CRESY five years ago would be worth $24,972 today (with dividends reinvested), compared to $321 for BIOX. Over the past 12 months, CRESY leads with a +13.6% total return vs BIOX's -88.4%. The 3-year compound annual growth rate (CAGR) favors CRESY at 35.0% vs BIOX's -63.7% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -6.9% | -64.3% |
| 1-Year ReturnPast 12 months | +13.6% | -88.4% |
| 3-Year ReturnCumulative with dividends | +146.2% | -95.2% |
| 5-Year ReturnCumulative with dividends | +149.7% | -96.8% |
| 10-Year ReturnCumulative with dividends | +68.4% | -95.0% |
| CAGR (3Y)Annualised 3-year return | +35.0% | -63.7% |
Risk & Volatility
CRESY leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
CRESY is the less volatile stock with a 1.19 beta — it tends to amplify market swings less than BIOX's 1.94 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CRESY currently trades 81.2% from its 52-week high vs BIOX's 9.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.19x | 1.94x |
| 52-Week HighHighest price in past year | $14.21 | $5.18 |
| 52-Week LowLowest price in past year | $8.32 | $0.35 |
| % of 52W HighCurrent price vs 52-week peak | +81.2% | +9.3% |
| RSI (14)Momentum oscillator 0–100 | 41.4 | 42.8 |
| Avg Volume (50D)Average daily shares traded | 271K | 808K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
CRESY is the only dividend payer here at 8.21% yield — a key consideration for income-focused portfolios.
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — |
| Price TargetConsensus 12-month target | $12.68 | — |
| # AnalystsCovering analysts | 1 | — |
| Dividend YieldAnnual dividend ÷ price | +8.2% | — |
| Dividend StreakConsecutive years of raises | 0 | — |
| Dividend / ShareAnnual DPS | $1320.71 | — |
| Buyback YieldShare repurchases ÷ mkt cap | +1.6% | +3.0% |
CRESY leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). BIOX leads in 1 (Valuation Metrics).
CRESY vs BIOX: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is CRESY or BIOX a better buy right now?
For growth investors, Cresud Sociedad Anónima, Comercial, Inmobiliaria, Financiera y Agropecuaria (CRESY) is the stronger pick with 28.
5% revenue growth year-over-year, versus -28. 3% for Bioceres Crop Solutions Corp. (BIOX). Cresud Sociedad Anónima, Comercial, Inmobiliaria, Financiera y Agropecuaria (CRESY) offers the better valuation at 9999. 0x trailing P/E, making it the more compelling value choice. Analysts rate Cresud Sociedad Anónima, Comercial, Inmobiliaria, Financiera y Agropecuaria (CRESY) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — CRESY or BIOX?
Over the past 5 years, Cresud Sociedad Anónima, Comercial, Inmobiliaria, Financiera y Agropecuaria (CRESY) delivered a total return of +149.
7%, compared to -96. 8% for Bioceres Crop Solutions Corp. (BIOX). Over 10 years, the gap is even starker: CRESY returned +68. 4% versus BIOX's -95. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — CRESY or BIOX?
By beta (market sensitivity over 5 years), Cresud Sociedad Anónima, Comercial, Inmobiliaria, Financiera y Agropecuaria (CRESY) is the lower-risk stock at 1.
19β versus Bioceres Crop Solutions Corp. 's 1. 94β — meaning BIOX is approximately 63% more volatile than CRESY relative to the S&P 500. On balance sheet safety, Cresud Sociedad Anónima, Comercial, Inmobiliaria, Financiera y Agropecuaria (CRESY) carries a lower debt/equity ratio of 66% versus 94% for Bioceres Crop Solutions Corp. — giving it more financial flexibility in a downturn.
04Which is growing faster — CRESY or BIOX?
By revenue growth (latest reported year), Cresud Sociedad Anónima, Comercial, Inmobiliaria, Financiera y Agropecuaria (CRESY) is pulling ahead at 28.
5% versus -28. 3% for Bioceres Crop Solutions Corp. (BIOX). On earnings-per-share growth, the picture is similar: Cresud Sociedad Anónima, Comercial, Inmobiliaria, Financiera y Agropecuaria grew EPS -99. 9% year-over-year, compared to -1704. 7% for Bioceres Crop Solutions Corp.. Over a 3-year CAGR, CRESY leads at 6. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — CRESY or BIOX?
Cresud Sociedad Anónima, Comercial, Inmobiliaria, Financiera y Agropecuaria (CRESY) is the more profitable company, earning 10.
5% net margin versus -15. 5% for Bioceres Crop Solutions Corp. — meaning it keeps 10. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CRESY leads at 24. 2% versus -1. 1% for BIOX. At the gross margin level — before operating expenses — CRESY leads at 39. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — CRESY or BIOX?
In this comparison, CRESY (8.
2% yield) pays a dividend. BIOX does not pay a meaningful dividend and should not be held primarily for income.
07Is CRESY or BIOX better for a retirement portfolio?
For long-horizon retirement investors, Cresud Sociedad Anónima, Comercial, Inmobiliaria, Financiera y Agropecuaria (CRESY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.
19), 8. 2% yield). Bioceres Crop Solutions Corp. (BIOX) carries a higher beta of 1. 94 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CRESY: +68. 4%, BIOX: -95. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between CRESY and BIOX?
These companies operate in different sectors (CRESY (Industrials) and BIOX (Basic Materials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: CRESY is a small-cap high-growth stock; BIOX is a small-cap quality compounder stock. CRESY pays a dividend while BIOX does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.